BridgeBio Pharma (BBIO) Consolidated Net Income (2018 - 2026)

BridgeBio Pharma's Consolidated Net Income history runs 9 years deep, the most recent figure standing at -$112.7 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 3.81% year-over-year to -$112.7 million; the TTM figure through Mar 2026 stood at -$676.0 million (down 8.29% YoY), while the FY2025 annual figure was -$732.9 million, down 34.89% from the prior year.
• Consolidated Net Income came in at -$112.7 million for Q1 2026 at BridgeBio Pharma, up from -$194.6 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$19.1 million in Q1 2024 to a low of -$267.4 million in Q4 2024.
• A 5-year average of -$151.5 million and a median of -$162.2 million in 2023 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income jumped 86.59% in 2024 and slumped 514.64% in 2025, its largest moves.
• BridgeBio Pharma's Consolidated Net Income stood at -$145.1 million in 2022, then sank by 32.37% to -$192.1 million in 2023, then plunged by 39.19% to -$267.4 million in 2024, then gained by 27.21% to -$194.6 million in 2025, then surged by 42.12% to -$112.7 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$112.7 million, -$194.6 million, and -$185.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison